APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Serplulimab Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Serplulimab Injection Market Outlook and Growth Opportunities 2026

Report ID 174034760422 December 2025191 pages

Choose your research edition.

Industry ResearchSerplulimab Injection Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Serplulimab Injection Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Serplulimab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Serplulimab Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Serplulimab Injection Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Serplulimab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Serplulimab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Serplulimab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Serplulimab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Serplulimab Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Serplulimab Injection market include Shanghai Henlius Biotech. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Serplulimab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Serplulimab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Serplulimab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Serplulimab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Serplulimab Injection Segment by Company

Shanghai Henlius Biotech

Serplulimab Injection Segment by Type

100mg/10ml

Others

Serplulimab Injection Segment by Application

Hospitals

Clinics

Others

Serplulimab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Serplulimab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Serplulimab Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Serplulimab Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Serplulimab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Serplulimab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Serplulimab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Serplulimab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Serplulimab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Serplulimab Injection industry.

Chapter 3: Detailed analysis of Serplulimab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Serplulimab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Serplulimab Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Serplulimab Injection Industry Trends Table 2. Serplulimab Injection Industry Drivers Table 3. Serplulimab Injection Industry Opportunities and Challenges Table 4. Serplulimab Injection Industry Restraints Table 5. Global Serplulimab Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Serplulimab Injection Revenue Share by Company (2021-2026) Table 7. Global Serplulimab Injection Sales Volume by Company (k units) & (2021-2026) Table 8. Global Serplulimab Injection Sales Volume Share by Company (2021-2026) Table 9. Global Serplulimab Injection Average Price (US$/unit) of Company (2021-2026) Table 10. Global Serplulimab Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Serplulimab Injection Key Company Manufacturing Base & Headquarters Table 12. Global Serplulimab Injection Company, Product Type & Application Table 13. Global Serplulimab Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Serplulimab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg/10ml Table 18. Significant Companies of Others Table 19. Global Serplulimab Injection Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Serplulimab Injection Sales Volume by Type (2021-2026) & (k units) Table 21. Global Serplulimab Injection Sales Volume by Type (2027-2032) & (k units) Table 22. Global Serplulimab Injection Sales Volume Share by Type (2021-2026) Table 23. Global Serplulimab Injection Sales Volume Share by Type (2027-2032) Table 24. Global Serplulimab Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Serplulimab Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Serplulimab Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Serplulimab Injection Sales Value Share by Type (2021-2026) Table 28. Global Serplulimab Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Others Table 32. Global Serplulimab Injection Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Serplulimab Injection Sales Volume by Application (2021-2026) & (k units) Table 34. Global Serplulimab Injection Sales Volume by Application (2027-2032) & (k units) Table 35. Global Serplulimab Injection Sales Volume Share by Application (2021-2026) Table 36. Global Serplulimab Injection Sales Volume Share by Application (2027-2032) Table 37. Global Serplulimab Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Serplulimab Injection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Serplulimab Injection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Serplulimab Injection Sales Value Share by Application (2021-2026) Table 41. Global Serplulimab Injection Sales Value Share by Application (2027-2032) Table 42. Global Serplulimab Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Serplulimab Injection Sales by Region (2021-2026) & (k units) Table 44. Global Serplulimab Injection Sales Market Share by Region (2021-2026) Table 45. Global Serplulimab Injection Sales by Region (2027-2032) & (k units) Table 46. Global Serplulimab Injection Sales Market Share by Region (2027-2032) Table 47. Global Serplulimab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Serplulimab Injection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Serplulimab Injection Sales Value Share by Region (2021-2026) Table 50. Global Serplulimab Injection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Serplulimab Injection Sales Value Share by Region (2027-2032) Table 52. Global Serplulimab Injection Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Serplulimab Injection Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Serplulimab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Serplulimab Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Serplulimab Injection Sales by Country (2021-2026) & (k units) Table 57. Global Serplulimab Injection Sales Market Share by Country (2021-2026) Table 58. Global Serplulimab Injection Sales by Country (2027-2032) & (k units) Table 59. Global Serplulimab Injection Sales Market Share by Country (2027-2032) Table 60. Global Serplulimab Injection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Serplulimab Injection Sales Value Market Share by Country (2021-2026) Table 62. Global Serplulimab Injection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Serplulimab Injection Sales Value Market Share by Country (2027-2032) Table 64. Shanghai Henlius Biotech Company Information Table 65. Shanghai Henlius Biotech Business Overview Table 66. Shanghai Henlius Biotech Serplulimab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Shanghai Henlius Biotech Serplulimab Injection Product Portfolio Table 68. Shanghai Henlius Biotech Recent Development Table 69. Key Raw Materials Table 70. Raw Materials Key Suppliers Table 71. Serplulimab Injection Distributors List Table 72. Serplulimab Injection Customers List Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Serplulimab Injection Product Image Figure 2. Global Serplulimab Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Serplulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Serplulimab Injection Sales (2021-2032) & (k units) Figure 5. Global Serplulimab Injection Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Serplulimab Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg/10ml Image Figure 10. Others Image Figure 11. Global Serplulimab Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Serplulimab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Serplulimab Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Serplulimab Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Serplulimab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Serplulimab Injection Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Serplulimab Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Serplulimab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Serplulimab Injection Sales Volume Share by Application (2021-2032) Figure 23. Global Serplulimab Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Serplulimab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Serplulimab Injection Sales Value Share by Application (2021-2032) Figure 26. Global Serplulimab Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Serplulimab Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Serplulimab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Serplulimab Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Serplulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Serplulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Serplulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Serplulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Serplulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Serplulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Serplulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Serplulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Serplulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Serplulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Serplulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Serplulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Serplulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Serplulimab Injection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Serplulimab Injection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg/10ml
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Shanghai Henlius Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Serplulimab Injection Sales Value (2021-2032)
  4. 1.2.2 Global Serplulimab Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Serplulimab Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Serplulimab Injection Market Dynamics
  1. 2.1 Serplulimab Injection Industry Trends
  2. 2.2 Serplulimab Injection Industry Drivers
  3. 2.3 Serplulimab Injection Industry Opportunities and Challenges
  4. 2.4 Serplulimab Injection Industry Restraints
3 Serplulimab Injection Market by Company
  1. 3.1 Global Serplulimab Injection Company Revenue Ranking in 2025
  2. 3.2 Global Serplulimab Injection Revenue by Company (2021-2026)
  3. 3.3 Global Serplulimab Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Serplulimab Injection Average Price by Company (2021-2026)
  5. 3.5 Global Serplulimab Injection Company Ranking (2024-2026)
  6. 3.6 Global Serplulimab Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Serplulimab Injection Company Product Type and Application
  8. 3.8 Global Serplulimab Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Serplulimab Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Serplulimab Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Serplulimab Injection Market by Type
  1. 4.1 Serplulimab Injection Type Introduction
  2. 4.1.1 100mg/10ml
  3. 4.1.2 Others
  4. 4.2 Global Serplulimab Injection Sales Volume by Type
  5. 4.2.1 Global Serplulimab Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Serplulimab Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Serplulimab Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Serplulimab Injection Sales Value by Type
  9. 4.3.1 Global Serplulimab Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Serplulimab Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Serplulimab Injection Sales Value Share by Type (2021-2032)
5 Serplulimab Injection Market by Application
  1. 5.1 Serplulimab Injection Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Serplulimab Injection Sales Volume by Application
  6. 5.2.1 Global Serplulimab Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Serplulimab Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Serplulimab Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Serplulimab Injection Sales Value by Application
  10. 5.3.1 Global Serplulimab Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Serplulimab Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Serplulimab Injection Sales Value Share by Application (2021-2032)
6 Serplulimab Injection Regional Sales and Value Analysis
  1. 6.1 Global Serplulimab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Serplulimab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Serplulimab Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Serplulimab Injection Sales by Region (2027-2032)
  5. 6.3 Global Serplulimab Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Serplulimab Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Serplulimab Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Serplulimab Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Serplulimab Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Serplulimab Injection Sales Value (2021-2032)
  12. 6.6.2 North America Serplulimab Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Serplulimab Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Serplulimab Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Serplulimab Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Serplulimab Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Serplulimab Injection Sales Value (2021-2032)
  21. 6.9.2 South America Serplulimab Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Serplulimab Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Serplulimab Injection Sales Value Share by Country, 2025 VS 2032
7 Serplulimab Injection Country-level Sales and Value Analysis
  1. 7.1 Global Serplulimab Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Serplulimab Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Serplulimab Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Serplulimab Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Serplulimab Injection Sales by Country (2027-2032)
  6. 7.4 Global Serplulimab Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Serplulimab Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Serplulimab Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Serplulimab Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Serplulimab Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Serplulimab Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Serplulimab Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Serplulimab Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Serplulimab Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Serplulimab Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Serplulimab Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Serplulimab Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Serplulimab Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Serplulimab Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Serplulimab Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Serplulimab Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Serplulimab Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Serplulimab Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Serplulimab Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Serplulimab Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Serplulimab Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Serplulimab Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Serplulimab Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Serplulimab Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Serplulimab Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Serplulimab Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Serplulimab Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Serplulimab Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Serplulimab Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Serplulimab Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Serplulimab Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Serplulimab Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Serplulimab Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Henlius Biotech
  2. 8.1.1 Shanghai Henlius Biotech Company Information
  3. 8.1.2 Shanghai Henlius Biotech Business Overview
  4. 8.1.3 Shanghai Henlius Biotech Serplulimab Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Henlius Biotech Serplulimab Injection Product Portfolio
  6. 8.1.5 Shanghai Henlius Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Serplulimab Injection Value Chain Analysis
  2. 9.1.1 Serplulimab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Serplulimab Injection Sales Mode & Process
  6. 9.2 Serplulimab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Serplulimab Injection Distributors
  9. 9.2.3 Serplulimab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst